Want to see ARTL full AI Analyst Report?
Total Valuation
Artelo Biosciences has a market cap or net worth of $3.66M. The enterprise value is -$6.55M.
Market Cap$3.66M
Enterprise Value-$6.55M
Share Statistics
Artelo Biosciences has 3,485,540 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding3,485,540
Owned by Insiders9.46%
Owned by Institutions0.38%
Financial Efficiency
Artelo Biosciences’s return on equity (ROE) is 10.13 and return on invested capital (ROIC) is 1919.87%.
Return on Equity (ROE)10.13
Return on Assets (ROA)-4.60
Return on Invested Capital (ROIC)1919.87%
Return on Capital Employed (ROCE)9.17
Revenue Per Employee0.00
Profits Per Employee-1.84M
Employee Count7
Asset Turnover0.00
Inventory Turnover0.00
Valuation Ratios
The current PE Ratio of Artelo Biosciences is ―. Artelo Biosciences’s PEG ratio is -0.00051.
PE Ratio―
PS Ratio0.00
PB Ratio-2.26
Price to Fair Value-2.26
Price to FCF-0.34
Price to Operating Cash Flow-0.10
PEG Ratio-0.00051
Income Statement
In the last 12 months, Artelo Biosciences had revenue of 0.00 and earned -12.88M in profits. Earnings per share was -5.47.
Revenue0.00
Gross Profit0.00
Operating Income-11.40M
Pretax Income-12.88M
Net Income-12.88M
EBITDA-12.54M
Earnings Per Share (EPS)-5.47
Cash Flow
In the last 12 months, operating cash flow was -8.11M and capital expenditures 0.00, giving a free cash flow of -8.11M billion.
Operating Cash Flow-8.11M
Free Cash Flow-8.11M
Free Cash Flow per Share-2.33
Dividends & Yields
Artelo Biosciences pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta-0.74
52-Week Price Change-97.45%
50-Day Moving Average1.57
200-Day Moving Average5.18
Relative Strength Index (RSI)41.23
Average Volume (3m)89.20K
Important Dates
Artelo Biosciences upcoming earnings date is Aug 12, 2026, TBA (Confirmed).
Last Earnings DateMay 14, 2026
Next Earnings DateAug 12, 2026
Ex-Dividend Date―
Financial Position
Artelo Biosciences as a current ratio of 0.17, with Debt / Equity ratio of 10.78%
Current Ratio0.17
Quick Ratio0.17
Debt to Market Cap0.21
Net Debt to EBITDA>-0.01
Interest Coverage Ratio-58.78
Taxes
In the past 12 months, Artelo Biosciences has paid 0.00 in taxes.
Income Tax0.00
Effective Tax Rate0.00
Enterprise Valuation
Artelo Biosciences EV to EBITDA ratio is -0.24, with an EV/FCF ratio of -0.35.
EV to Sales0.00
EV to EBITDA-0.24
EV to Free Cash Flow-0.35
EV to Operating Cash Flow-0.35
Balance Sheet
Artelo Biosciences has $10.27M in cash and marketable securities with $719.00K in debt, giving a net cash position of $9.55M billion.
Cash & Marketable Securities$10.27M
Total Debt$719.00K
Net Cash$9.55M
Net Cash Per Share$2.74
Tangible Book Value Per Share-$1.41
Margins
Gross margin is 0.00%, with operating margin of 0.00%, and net profit margin of 0.00%.
Gross Margin0.00%
Operating Margin0.00%
Pretax Margin0.00%
Net Profit Margin0.00%
EBITDA Margin0.00%
EBIT Margin0.00%
Analyst Forecast
The average price target for Artelo Biosciences is ―, which is 11.43% higher than the current price. The consensus rating is ―
Price Target―
Price Target Upside―
Analyst Consensus―
Analyst Count0
Revenue Growth Forecast―
EPS Growth Forecast27.77%